Navigation Links
InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
Date:4/23/2013

BOSTON and TEL-AVIV, Israel, April 23, 2013 /PRNewswire/ --

InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ Embolic Protection Stent (EPS), announced today that on April 19, 2013, the Company received an approval with conditions for its Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA). An approval with conditions indicates that the FDA concurs with the overall trial design and while minor details are being finalized, allows the company to initiate enrollment in the MASTER II IDE trial.

The multi-center, randomized trial will consist of 1,114 patients suffering from ST Elevation Myocardial Infarction (STEMI), throughout 35 sites in the U.S. and an additional 35 sites in Europe, and will support the Company's application to market its MGuard™ Prime MicroNet™ covered coronary stent system in the US.

Gregg Stone M.D ., of The Cardiovascular Research Foundation, and Jose P. S. Henriques M.D ., of the Academic Medical Center Amsterdam in the Netherlands, will serve as Principal Investigators for the trial, which will consist of two co-primary endpoints: superiority in complete ST resolution and non-inferiority in death and target vesselmyocardial infarction. In addition, a 356 patient sub-study will be conducted to assess the effect of MGuard™ EPS on vessel infarct size, as measured through cardiac Magnetic Resonance Imaging (MRI).

"Receiving this approval to commence our FDA trial is a significant milestone." commented Alan Milinazzo , InspireMD's CEO and President. Mr. Milinazzo further noted, that "This trial will provide an excellent opportunity to validate the safety and effectiveness of MGuard™ EPS in another large multi-c
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and Minimally ... medical device company, have formally agreed to an exclusive ... in Japan . It is anticipated that ... in the latter half of 2015. ... in endoscopic surgery market in Japan . ...
(Date:8/22/2014)...  Mark Riccio, director of Cornell University,s multi-scale ... the online crowd-funding platform Kickstarter to bring non-invasive ... and would-be superheros everywhere: "for FREE." Riccio,s campaign, ... if you had Superman,s X-ray vision?" The campaign ... from elementary through high school students, academic institutions, ...
(Date:8/22/2014)... 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... trading on The NASDAQ Stock Market under the ticker ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Systems, Inc. , the maker of TrackWise ... in enterprise quality and compliance management solutions, today ... provider of high-quality generic pharmaceuticals, has selected TrackWise® ...   As the manufacturer of more ...
... for Full Year Fiscal 2010 -- WEIFANG, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
Cached Medicine Technology:Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 2Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 3Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management 4Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 2Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 3Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 4Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 5Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 6Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 7Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 8Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 9
(Date:8/22/2014)... The improved access to antiretroviral drugs ... developing world, has led to the decline in the ... due to AIDS globally. However, despite the fact that ... patients becoming affected by the virus is on the ... all related organisations and stakeholders, by 2015, significant investments ...
(Date:8/22/2014)... A national leader in home delivery of ... room to grow. , Headquarters for the provider of sterile-use ... building at 8516 N.W. Expressway in Oklahoma City. , ... Oklahoma’s best places to work by OKCBiz magazine – demanded ... 120 in the past two years, and staff count grew ...
(Date:8/22/2014)... 2014 (HealthDay News) -- People who use reduced-nicotine cigarettes ... levels of nicotine, according to a new study. ... other smokers, the researchers say. The month-long study ... smoked regular cigarettes with nicotine emission levels of 1.2 ... switched to reduced-nicotine cigarettes for the next three weeks. ...
(Date:8/22/2014)... years, several breakthrough treatments have become available for ... benefit from these treatments can be pre-identified by ... For example, patients whose lung cancer is driven ... benefit from the drug crizotinib, which targets this ... to replicate this success by matching different drugs ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ticket Down ... tickets in Kalamazoo, New Orleans, Albuquerque and Rapid City. ... the “Long Island Medium,” Theresa Caputo, allows just that. Caputo ... She is part of a close knit family who began ... with a spiritual healer, realized she had a chance to ...
Breaking Medicine News(10 mins):Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2
... likely than Caucasians and men to undergo bone marrow ... the conclusion of a new analysis published early online ... American Cancer Society. The study,s results indicate that additional ... access to bone marrow transplantation and also that the ...
... ... ... Readers will be struck by the illuminative work of a mature poet as author Brad ... its name, this reflective anthology reveals the profound emotions and sentiments of a man who, ...
... “The reviews were amazing. ... BMEGateway to give a symposium to our loyal client base that was enjoyable and memorable on ... like this.” , ... (PRWEB) May 23, 2010 -- BMEGateway, the national leader in independent medical evaluation, peer/medical review ...
... people to protect their ears when going to firework displays, ... most common sounds of summer can expose listeners to permanent ... was sounded by David Coffin, director of Ball State University,s ... come in the form of the pop of fireworks, the ...
... ... celiac disease , ... (PRWEB) May 22, 2010 -- LoveToKnow, Inc. has launched a new Web site channel that ... addition, as part of a campaign to help people with these issues, the company said ...
... ... residential solar energy systems in Bensalem, Pennsylvania. The systems are the first operating systems ... the region. The projects were primarily funded through the Pennsylvania Sunshine Fund and Federal ... West Chester, ...
Cached Medicine News:Health News:African-Americans and women are less likely to undergo bone marrow transplantation 2Health News:The Heart of the Prisoner Revealed 2Health News:BMEGateway's 20th Anniversary Insurance Symposium considered a “Tremendous” Success 2Health News:Summer Sounds Can Lead to Hearing Loss 2Health News:LoveToKnow.com Launches Gluten Free Channel and Will Donate to National Foundation for Celiac Awareness 2Health News:LoveToKnow.com Launches Gluten Free Channel and Will Donate to National Foundation for Celiac Awareness 3Health News:Pennsylvania's Newest Power Companies Right in Your Neighbor's Back Yard 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: